Seer, Inc. (SEER)
NASDAQ: SEER · Real-Time Price · USD
1.570
-0.020 (-1.26%)
At close: Nov 13, 2026, 4:00 PM EST
1.555
-0.015 (-0.96%)
After-hours: Nov 13, 2026, 7:30 PM EST
Seer, Inc. Revenue
Seer, Inc. had revenue of $3.98M in the quarter ending September 30, 2026, a decrease of -3.40%. This brings the company's total for the last twelve months to $14.08M, down -14.04% year-over-year. In the year 2025, Seer, Inc. had annual revenue of $16.58M with 16.99% growth. That makes Seer, Inc. the 35,734th largest company in the world by revenue and 4,691st in the United States.
Revenue (ttm)
$14.08M
Revenue Growth
-14.04%
P/S Ratio
6.18
Revenue / Employee
$113,524
Employees
124
Market Cap
86.93M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.58M | 2.41M | 16.99% |
| Dec 31, 2024 | 14.17M | -2.49M | -14.95% |
| Dec 31, 2023 | 16.66M | 1.17M | 7.54% |
| Dec 31, 2022 | 15.49M | 8.88M | 134.14% |
| Dec 31, 2021 | 6.62M | 5.96M | 908.69% |
| Dec 31, 2020 | 656.00K | 540.00K | 465.52% |
| Dec 31, 2019 | 116.00K | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Black Diamond Therapeutics | 70.00M |
| Cellectis | 63.82M |
| ImmuCell | 30.68M |
| Cibus | 4.35M |
| Milestone Pharmaceuticals | 2.34M |
| Genelux | 8.00K |
SEER News
- 3 days ago - Seer, Inc. Earnings Call Transcript: Q3 2026 - Transcripts
- 3 days ago - Seer, Inc. Earnings release: Q3 2026 - Filings
- 3 days ago - Seer, Inc. Quarterly report: Q3 2026 - Filings
- 3 days ago - Seer, Inc. Slides: Q3 2026 - Filings
- 3 days ago - Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance - GlobeNewsWire
- 8 days ago - Seer secures patent enforcement win against Nanomics Biotechnology - TheFly
- 8 days ago - Seer Secures Key Victory in ITC Patent Dispute as Investigative Staff Backs All Requested Remedies Against Nanomics - GlobeNewsWire
- 11 days ago - Radoff-JEC issues open letter on Seer’s decision to remain public - TheFly